In a major leap for India's biotechnology sector, a Hyderabad startup is pioneering a new frontier in cancer treatment. By merging the power of artificial intelligence with advanced biology, it's creating personalised vaccines at a new, dedicated RNA
facility.
A New Hub for Hope: The RNA Foundry
Hyderabad is cementing its status as a global life sciences hub with the launch of the RNA Foundry, a state-of-the-art research and manufacturing facility. This centre is the brainchild of PopVax, a local biotechnology startup, established in collaboration with Stochastic Sciences. Founded in 2021 by Soham Sankaran, a computer scientist turned biotech entrepreneur, PopVax aims to revolutionise how we fight complex diseases. The new facility isn't just a laboratory; it is an integrated centre designed to handle everything from vaccine design and RNA production to final formulation and quality control, all under one roof. This development places Hyderabad at the core of India’s growing capabilities in next-generation medical technology.
The Science Simplified: What Are Personalised mRNA Vaccines?
At the heart of this innovation is messenger RNA (mRNA) technology. Think of mRNA as a temporary instruction manual for your body's cells. In this case, the instructions teach your immune system how to recognise and fight cancer cells. Unlike traditional 'one-size-fits-all' medicines, PopVax's approach is deeply personal. Every cancer is genetically unique. The process begins by sequencing a patient's tumour to identify its specific mutations. These mutations create abnormal proteins called 'neoantigens', which act like red flags on cancer cells. The goal is to create a vaccine that tells the immune system, 'go find these specific flags and attack'. This targeted approach holds the promise of being more effective and having fewer side effects than many conventional treatments.
Where Artificial Intelligence Meets Biology
The sheer volume of genetic data in a single tumour is immense, making it nearly impossible for humans to analyse manually. This is where machine learning and artificial intelligence (AI) become critical. PopVax uses sophisticated algorithms to sift through a patient's tumour genetics and predict which neoantigens are most likely to trigger a strong immune response. By combining AI-powered protein design with its mRNA platform, the company can dramatically accelerate the creation of a customised vaccine. Founder Soham Sankaran's background in computer science and robotics is a driving force behind this fusion of code and cells. The company has an ambitious goal: to produce over 100 personalised cancer vaccine candidates within the next year, a timeline made possible only through this high-tech approach.
Hyderabad's 'Genome Valley' on the Global Stage
PopVax's initiative is not happening in a vacuum. It is a landmark development for Hyderabad's Genome Valley, a thriving bio_pharma business park that has attracted global giants like Novartis and Amgen. This ecosystem, which first gained international recognition for producing India's first homegrown COVID_19 vaccine, provides fertile ground for such ambitious projects. The presence of world_class infrastructure and a deep talent pool allows startups like PopVax to bridge the gap between discovery and clinical application. The establishment of the RNA Foundry, which is compliant with Good Manufacturing Practices (GMP), signals a new maturity for the Indian biotech industry, moving from a service provider to an innovator on the world stage.
